GcMAF interacts with systemic macrophages within a few days after its administration and increases their phagocytic activity. It also increases the maturation of dendritic cells.
Physicians have reported positive clinical results from the use of gcmaf in patients with different types of cancer. This article will discuss some of these cases.
It Activates Macrophages
GcMAF activates macrophages to support phagocytosis and antigen-presenting activity, and it also facilitates the production of antibodies by these cells. It also stimulates immune-cell progenitor cells for extensive proliferation, which increases the number of immature lymphocytes that can be converted to macrophages.
Yamamoto patented his GcMAF discovery and claims that it can treat many different kinds of cancers, as well as infectious envelope viruses like HIV. His research is controversial, however, and his 2008 paper on the link between GcMAF and HIV has been retracted by the journal that published it.
GcMAF is available as an injectable, and can be used in combination with Sonodynamic Therapy (SDT), Photodynamic Therapy, Maitake Extract, Coley Vaccine, High dose IV Vitamin C, Low Dose Naltrexone and Alpha-Lipoic Acid. Beware of unauthorized sellers that offer it online. The Guernsey Medicines and Healthcare Products Regulatory Agency has warned that these products may pose a significant risk to people’s health because they are not regulated by the authority.
It Activates Natural Killer Cells
Activated GcMAF stimulates the macrophages, which are specialized white blood cells that catch and destroy foreign particles such as viruses, bacteria, and germs. They are found throughout the body, including the bone marrow, spleen, liver, lungs, and gut. They also act as a reservoir for immune system proteins and stimulate lymphocytes and natural killer cells to attack pathogens.
Macrophages induced by GcMAF are activated with a wide variety of receptors that recognize the abnormality of cancerous cell surface and kill cancer cells [35]. This effect of GcMAF on cancer cells is independent of anemia, suggesting that even patients who are severely anemic can receive effective treatment.
Some online sellers offer injections of bovine colostrum, which they claim contains GcMAF. However, these products have not been tested for quality, safety, or efficacy and may contain harmful chemicals. They are usually sold through social media to avoid government regulation. We offer Second Generation GcMAF that is manufactured in our own sterile facility from human serum which is carefully screened for activity and sterility.
It Activates Dendritic Cells
GcMAF activates dendritic cells, which are then able to present processed antigens to T-cells for an immune response. This is how GcMAF supports the formation of antibodies against cancer.
Gc MAF can be combined with most therapies, including Sonodynamic Therapy and Photodynamic Therapy (SDT and PDT), Maitake Extract, Coley Vaccine Fluid, high dose IV Vitamin C, Low Dose Naltrexone and Alpha-Lipoic Acid. It is especially effective in synergy with targeted therapies that don’t harm the immune system.
In addition to this, GcMAF has been shown to increase the phagocytic activity of macrophages and promote polarization toward the M1 phenotype, thus enhancing their tumoricidal properties [42]. This is one of the main reasons that Karanahan has proven to be so effective against prostate cancer.
It Activates T Cells
GcMAF is naturally produced in the human body and it stimulates macrophages to kill cancer cells, foreign invaders like bacteria and viruses, and serious illnesses like cancer, HIV and viral hepatitis. However, the production of this potent activator is blocked by an enzyme called Nagalase.
Inflammation primes the production of a soluble, protein-based alkylglycerol, Gc protein-derived Macrophage Activating Factor (GcMAF) [1]. It is deglycosylated by plasma Nagalase in a stepwise manner via immobilized b-galactosidase from activated B cells and sialidase from T cells to generate MAF.
This potent MAF is the most effective cancer-killing agent known to date. Weekly administration of 100 ng of GcMAF to nonanemic patients has demonstrated curative rates in a variety of tumors including breast, prostate, lung, colon, stomach and liver (including mesothelioma), pancreatic cancer, melanoma, and head/neck carcinoma. Curative rates were always faster in undifferentiated adenocarcinomas than well-differentiated squamous carcinomas.